{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:18:22Z","timestamp":1793657902136,"version":"4.5.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["CRG\/2018\/002159"],"award-info":[{"award-number":["CRG\/2018\/002159"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research","doi-asserted-by":"publisher","award":["09\/677(0033)\/2018-EMR-I"],"award-info":[{"award-number":["09\/677(0033)\/2018-EMR-I"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Novel derivatives possessing imidazo[1,2-<jats:italic>a<\/jats:italic>]pyrazine and 1<jats:italic>H<\/jats:italic>-benzo[<jats:italic>d<\/jats:italic>]imidazole scaffolds were synthesized using Suzuki-Miyaura cross-coupling reactions. <jats:italic>In vitro<\/jats:italic> anticancer activities against NCI-60 cancer cell panels were tested at 10\u2009<jats:italic>\u00b5<\/jats:italic>M concentration. The best results were obtained from substitution of two 1-cyclohexyl-1<jats:italic>H<\/jats:italic>-benzo[<jats:italic>d<\/jats:italic>]imidazole groups present at C-6 and C-8 positions of imidazo[1,2-<jats:italic>a<\/jats:italic>]pyrazine (<jats:bold>31<\/jats:bold>). Compound <jats:bold>31<\/jats:bold> was found to be cytotoxic against 51 cell lines and cytostatic against 8 cell lines with broad range of growth inhibitions (\u221298.48 to 98.86%). GI<jats:sub>50<\/jats:sub> value of compound <jats:bold>31<\/jats:bold> was found in the range of 0.80\u20132.87\u2009<jats:italic>\u00b5<\/jats:italic>M for 59 human cancer cell lines at five-dose concentration levels. DNA binding study of potent compound <jats:bold>31<\/jats:bold> was suggested that this compound was intercalated into DNA base pairs with binding constant of 1.25 \u00d7 10<jats:sup>4<\/jats:sup>\u2009M<jats:sup>\u22121<\/jats:sup>. Compound <jats:bold>31<\/jats:bold> showed effective binding with bovine serum albumin (BSA) and presented binding constant value of 3.79 \u00d710<jats:sup>4<\/jats:sup>\u2009M<jats:sup>-1<\/jats:sup>. Pharmacokinetic studies revealed that all compounds are following Lipinski\u2019s rule of five and expected to be orally active.<\/jats:p>","DOI":"10.1038\/s41598-020-63605-4","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T10:03:11Z","timestamp":1587031391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Synthesis, cytotoxicity, pharmacokinetic profile, binding with DNA and BSA of new imidazo[1,2-a]pyrazine-benzo[d]imidazol-5-yl hybrids"],"prefix":"10.1038","volume":"10","author":[{"given":"Iqubal","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Luxami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1935-7531","authenticated-orcid":false,"given":"Kamaldeep","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"63605_CR1","unstructured":"Global cancer report, World Health Organization, 2018. Available from, https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/cancer (accessed in April 2019)."},{"key":"63605_CR2","doi-asserted-by":"publisher","first-page":"8607","DOI":"10.1021\/jo034760e","volume":"68","author":"MK Cyranski","year":"2003","unstructured":"Cyranski, M. K., Gilski, M., Jaskolski, M. & Krygowski, T. M. On the aromatic character of the heterocyclic bases of DNA and RNA. J. Org. Chem. 68, 8607\u20138613 (2003).","journal-title":"J. Org. Chem."},{"key":"63605_CR3","doi-asserted-by":"crossref","unstructured":"Jemal, A. et al. Cancer statistics. C.A.: Cancer J. Clin. 58, 71\u201396 (2008).","DOI":"10.3322\/CA.2007.0010"},{"key":"63605_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2165\/00003088-200241060-00004","volume":"41","author":"R Danesi","year":"2002","unstructured":"Danesi, R., Fogli, S., Gennari, A., Conte, P. & Del Tacca, M. Pharmacokinetic pharmacodynamics relationships of the anthracycline anticancer drugs. Clin Pharmacokinet. 41, 431\u2013444 (2002).","journal-title":"Clin Pharmacokinet."},{"key":"63605_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1146\/annurev.bi.58.070189.002031","volume":"58","author":"LF Liu","year":"1989","unstructured":"Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58, 351\u2013375 (1989).","journal-title":"Annu. Rev. Biochem."},{"key":"63605_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.7326\/0003-4819-105-1-67","volume":"105","author":"TD Shenkenberg","year":"1986","unstructured":"Shenkenberg, T. D. & Von Hoff, D. D. Mitoxantrone: A new anticancer drug with significant clinical activity. Ann. Intern. Med. 105, 67\u201381 (1986).","journal-title":"Ann. Intern. Med."},{"key":"63605_CR7","unstructured":"Avendano, C. & Menendez, J. Medicinal chemistry of anticancer drugs; Elesevier BV: Oxford, 2008, Chapter 7."},{"key":"63605_CR8","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/jjco\/hyi149","volume":"35","author":"WJ Sung","year":"2005","unstructured":"Sung, W. J. et al. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia. Jpn. J. Clin Onco. 35, 612\u2013616 (2005).","journal-title":"Jpn. J. Clin Onco."},{"key":"63605_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejmech.2019.03.027","volume":"171","author":"A Mrozek-Wilczkiewicz","year":"2019","unstructured":"Mrozek-Wilczkiewicz, A., Malarz, K., Rejmund, M., Polanski, J. & Musiol, R. Anticancer activity of the thiosemicarbazones that are based on di-2-pyridine ketone and quinoline moiety. Eur. J. Med. Chem. 171, 180\u2013194 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"63605_CR10","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.bmcl.2018.01.008","volume":"28","author":"R-X Rong","year":"2018","unstructured":"Rong, R.-X. et al. Lysosomes-targeting imaging and anticancer properties of novel bis-naphthalimide derivatives. Bioorg. Med. Chem. Lett. 28, 742\u2013747 (2018).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"63605_CR11","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1021\/ja01176a030","volume":"71","author":"HA Benesi","year":"1949","unstructured":"Benesi, H. A. & Hildebrand, J. H. A spectrophotometric investigation of the interaction of iodine with aromatic hydrocarbons. J. Am. Chem. Soc. 71, 2703\u20132707 (1949).","journal-title":"J. Am. Chem. Soc."},{"key":"63605_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0003-2697(81)90474-7","volume":"114","author":"MR Eftink","year":"1981","unstructured":"Eftink, M. R. & Ghiron, C. A. Fluorescence quenching studies with proteins. Anal. Biochem. 114, 199\u2013227 (1981).","journal-title":"Anal. Biochem."},{"key":"63605_CR13","first-page":"4171","volume":"12","author":"JR Lakowicz","year":"1973","unstructured":"Lakowicz, J. R. & Weber, G. Quenching of protein fluorescence by oxygen. Detection of structural fluctuations in proteins on the nanosecond time scale. Biochemistry 12, 4171\u20134179 (1973).","journal-title":"Detection of structural fluctuations in proteins on the nanosecond time scale. Biochemistry"},{"key":"63605_CR14","first-page":"4161","volume":"12","author":"JR Lakowicz","year":"1973","unstructured":"Lakowicz, J. R. & Webber, G. Quenching of fluorescence by oxygen. Probe for structural fluctuations in macromolecules. Biochemistry 12, 4161\u20134170 (1973).","journal-title":"Probe for structural fluctuations in macromolecules. Biochemistry"},{"key":"63605_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1749-6632.1949.tb27297.x","volume":"51","author":"G Scatchard","year":"1949","unstructured":"Scatchard, G. The attractions of proteins for small molecules and ions. Ann. N. Y. Acad. Sci. 51, 660\u2013672 (1949).","journal-title":"N. Y. Acad. Sci."},{"key":"63605_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ejmech.2017.12.025","volume":"144","author":"P Srivastava","year":"2018","unstructured":"Srivastava, P., Singh, K., Verma, M., Sivakumar, S. & Patra, A. K. Photoactive platinum(II) complexes of nonsteroidal anti-inflammatory drug naproxen: Interaction with biological targets, antioxidant activity and cytotoxicity. Eur. J. Med. Chem. 144, 243\u2013254 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"63605_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/bip.1973.360120109","volume":"12","author":"VI Ivanov","year":"1973","unstructured":"Ivanov, V. I., Minchenkova, L. E., Schyolkina, A. K. & Poletayev, A. I. Different conformations of double-stranded nucleic acid in solution as revealed by circular dichroism. Biopolymers 12, 89\u2013110 (1973).","journal-title":"Biopolymers"},{"key":"63605_CR18","doi-asserted-by":"publisher","first-page":"28605","DOI":"10.1038\/srep28605","volume":"6","author":"M Deiana","year":"2016","unstructured":"Deiana, M. et al. Photochromic switching of the DNA helicity induced by azobenzene derivatives. Sci Rep. 6, 28605\u201328612 (2016).","journal-title":"Sci Rep."},{"key":"63605_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40364-017-0111-x","volume":"5","author":"SC Chien","year":"2017","unstructured":"Chien, S. C., Chen, C. Y., Lin, C. F. & Yeh, H. I. Critical appraisal of the role of serum albumin in cardiovascular disease. Biomark. Res. 5, 31\u201340 (2017).","journal-title":"Biomark. Res."},{"key":"63605_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40591-016-0048-8","volume":"4","author":"MT Larsen","year":"2016","unstructured":"Larsen, M. T., Kuhlmann, M., Hvam, M. L. & Howard, K. A. Albumin-based drug delivery: harnessing nature to cure disease. Mol. Cell. Ther. 4, 3\u201315 (2016).","journal-title":"Mol. Cell. Ther."},{"key":"63605_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jphotobiol.2015.10.023","volume":"153","author":"GF Shena","year":"2015","unstructured":"Shena, G. F., Liua, T. T., Wanga, Q., Jianga, M. & Shi, J. H. Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA). J. Photochem. Photobiol. B 153, 380\u2013390 (2015).","journal-title":"J. Photochem. Photobiol. B"},{"key":"63605_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jlumin.2013.03.026","volume":"142","author":"M Sarkar","year":"2013","unstructured":"Sarkar, M., Paul, S. S. & Mukherjea, K. K. Interaction of bovine serum albumin with a psychotropic drug alprazolam: Physicochemical, photophysical and molecular docking studies. J. Lumin. 142, 220\u2013230 (2013).","journal-title":"J. Lumin."},{"key":"63605_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliver Rev. 23, 4\u201325 (1997).","journal-title":"Adv. Drug. Deliver Rev."},{"key":"63605_CR24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ijbiomac.2018.05.009","volume":"116","author":"PP Utthra","year":"2018","unstructured":"Utthra, P. P. & Raman, N. Probing the potency of triazole tethered Schiff base complexes and the effect of substituents on their biological attributes. Int. J. Biol. Macromol. 116, 194\u2013207 (2018).","journal-title":"Int. J. Biol. Macromol."},{"key":"63605_CR25","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nprot.2016.051","volume":"11","author":"S Fortli","year":"2016","unstructured":"Fortli, S. et al. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat. Protoc. 11, 905\u2013919 (2016).","journal-title":"Nat. Protoc."},{"key":"63605_CR26","unstructured":"https:\/\/dtp.cancer.gov\/discovery_development\/nci-60\/methodology.htm (accessed in April 2019)."},{"key":"63605_CR27","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.saa.2009.11.014","volume":"75","author":"Y Nia","year":"2010","unstructured":"Nia, Y., Sub, S. & Kokotc, S. Spectrometric studies on the interaction of fluoroquinolones and bovine serum albumin. Spectrochim. Acta A 75, 547\u2013552 (2010).","journal-title":"Spectrochim. Acta A"},{"key":"63605_CR28","doi-asserted-by":"crossref","unstructured":"Lakowicz, J. R. Principles of fluorescence spectroscopy, third ed., Springer Science, New York, (2006).","DOI":"10.1007\/978-0-387-46312-4"},{"key":"63605_CR29","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jpba.2008.12.017","volume":"49","author":"Y Yue","year":"2009","unstructured":"Yue, Y., Chen, X. G., Qin, J. & Yao, X. J. Characterization of the mangiferin\u2013human serum albumin complex by spectroscopic and molecular modeling approaches. J. Pharm. Biomed. Anal. 49, 753\u2013759 (2009).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"63605_CR30","unstructured":"Molinspiration Cheminformatics, http:\/\/www.molinspiration.com\/cgi-bin\/properties. (accessed in April 2019)."},{"key":"63605_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jsps.2015.02.008","volume":"24","author":"A Husain","year":"2016","unstructured":"Husain, A. et al. Synthesis, molecular properties, toxicity and biological evaluation of some new substituted imidazolidine derivatives in search of potent anti-inflammatory agents. Saudi Pharm. J. 24, 104\u2013114 (2016).","journal-title":"Saudi Pharm. J."},{"key":"63605_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ddr.10023","volume":"55","author":"K Xu","year":"2002","unstructured":"Xu, K., Schwarz, P. M. & Ludue\u00f1a, R. F. Interaction of nocodazole with tubulin isotypes. Drug Dev. Res. 55, 91\u201396 (2002).","journal-title":"Drug Dev. Res."},{"key":"63605_CR33","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.1016\/j.ejmech.2010.08.035","volume":"45","author":"S Myadaraboina","year":"2010","unstructured":"Myadaraboina, S., Alla, M., Saddanapu, V., Bommenaa, V. R. & Addlagatta, A. Structure-activity relationship studies of imidazo[1,2-a]pyrazine derivatives against cancer cell lines. Eur. J. Med. Chem. 45, 5208\u20135216 (2010).","journal-title":"Eur. J. Med. Chem."},{"key":"63605_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00044-018-2258-x","volume":"28","author":"JA Romero","year":"2019","unstructured":"Romero, J. A. et al. Synthesis, antimalarial, antiproliferative, and apoptotic activities of benzimidazole-5-carboxamide derivatives. Med. Chem. Res. 28, 13\u201327 (2019).","journal-title":"Med. Chem. Res."},{"key":"63605_CR35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ejmech.2019.04.012","volume":"173","author":"I \u00c7elik","year":"2019","unstructured":"\u00c7elik, I. et al. Design, synthesis and docking studies of benzimidazole derivatives as potential EGFR inhibitors. Eur. J. Med. Chem. 173, 240\u2013249 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"63605_CR36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejmech.2017.05.058","volume":"137","author":"P Flores-Carrillo","year":"2017","unstructured":"Flores-Carrillo, P. et al. Synthesis, antiprotozoal activity, and chemoinformatic analysis of 2-(methylthio)-1H-benzimidazole-5-carboxamide derivatives: Identification of new selective giardicidal and trichomonicidal compounds. Eur. J. Med. Chem. 137, 211\u2013220 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"63605_CR37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.apsb.2015.05.003","volume":"5","author":"M Gaba","year":"2015","unstructured":"Gaba, M. et al. Benzimidazole derivatives: Search for GI-friendly anti-inflammatory analgesic agents. Acta Pharm. Sin. B. 5, 337\u2013342 (2015).","journal-title":"Acta Pharm. Sin. B."},{"key":"63605_CR38","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0968-0896(99)00019-X","volume":"7","author":"O Vitse","year":"1999","unstructured":"Vitse, O. et al. New imidazo[1,2-a]pyrazine derivatives with bronchodilatory and cyclic nucleotide phosphodiesterase inhibitory activities. Bioorg. Med. Chem. 7, 1059\u20131065 (1999).","journal-title":"Bioorg. Med. Chem."},{"key":"63605_CR39","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ejmech.2018.12.025","volume":"163","author":"SJ Kang","year":"2019","unstructured":"Kang, S. J. et al. Synthesis and anti-tumor activity of imidazopyrazines as TAK1 inhibitors. Eur. J. Med. Chem. 163, 660\u2013670 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"63605_CR40","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1021\/acscombsci.7b00173","volume":"20","author":"RN Rao","year":"2018","unstructured":"Rao, R. N., Balamurali, M. M., Maiti, B., Thakuria, R. & Chanda, K. Efficient access to imidazo[1,2-a]pyridines\/pyrazines\/pyrimidines via catalyst-free annulation reaction under microwave irradiation in green solvent. ACS Comb. Sci. 20, 164\u2013171 (2018).","journal-title":"ACS Comb. Sci."},{"key":"63605_CR41","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1016\/j.ejmech.2010.04.040","volume":"45","author":"FD Wael","year":"2010","unstructured":"Wael, F. D. et al. Chemistry around imidazopyrazine and ibuprofen: Discovery of novel fatty acid amide hydrolase (FAAH) inhibitors. Eur. J. Med. Chem. 45, 3564\u20133574 (2010).","journal-title":"Eur. J. Med. Chem."},{"key":"63605_CR42","first-page":"276","volume":"16","author":"S Myadaraboina","year":"2018","unstructured":"Myadaraboina, S., Alla, M., Parlapalli, A. & Manda, S. Novel imidazo[1,2-a]pyrazine derivatives: Design, synthesis, antioxidant and antimicrobial evaluations. Int. J. Chem. Sci. 16, 276\u2013288 (2018).","journal-title":"J. Chem. Sci."},{"key":"63605_CR43","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ejmech.2015.02.022","volume":"93","author":"B Huang","year":"2015","unstructured":"Huang, B. et al. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: Design, synthesis and biological evaluation of novel imidazo [1,2-a] pyrazines. Eur. J. Med. Chem. 93, 330\u2013337 (2015).","journal-title":"Eur. J. Med. Chem."},{"key":"63605_CR44","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1016\/j.ejmech.2011.07.006","volume":"46","author":"G Patel","year":"2011","unstructured":"Patel, G., Chavers, A. K., Chang, K.-H. & Shah, K. Synthesis of novel 1,2,4-oxadiazoles and analogues as potential anticancer agents. Eur. J. Med. Chem. 46, 3085\u20133092 (2011).","journal-title":"Eur. J. Med. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63605-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63605-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63605-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:11:54Z","timestamp":1670317914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63605-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["63605"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-63605-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]},"assertion":[{"value":"14 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6534"}}